Skip to main content

Table 2 Relationships between overall survival and WHO histological subtype according to the Masaoka–Koga staging system

From: Clinicopathological analysis of thymic malignancies with a consistent retrospective database in a single institution: from Tokyo Metropolitan Cancer Center

WHO classification (2004)

Noof Pts

 

Masaoka-Koga Stages

Survival rates (%)

 

(%)

I

II

III

IVa

IVb

5-yr OS

10-yr OS

Thymoma

119

 

52

31

12

18

6

85.4

71.5

A

5

2.7

4

1

0

0

0

100

-

AB

33

17.6

21

8

1

2

1

96.3

73.8

B1

19

10.2

11

5

0

2

1

90.9

68.2

B2

39

20.9

12

9

8

8

2

79.8

67.3

B3

15

8.0

1

5

3

5

1

61.6

61.6

Thymoma, other

8

4.3

3

3

0

1

1

68.6

68.8

Thymic carcinoma

68

36.4

0

6

10

16

36

33.8

2.3

Thymic carcinoma excluding NEC

57

30.5

0

5

9

13

30

33.0

4.1

NETT

11

5.9

0

1

1

3

6

27.3

9.1

Total

187

100.0

52

37

22

34

42

65.9

45.3

  1. WHO, World Health Organization; OS, overall survival; NETT, neuroendocrine thymic tumors.